Araris Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
23
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.14B
- Investors
-
1
Araris General Information
Description
Developer of an antibody-drug conjugate linker technology designed to pioneer targeted cancer therapies. The company offers a proprietary peptide linker platform and enzymatic conjugation tools, enabling pharmaceutical partners to attach payloads to off-the-shelf antibodies in a single step to create homogeneous and stable therapeutics for the treatment of non-Hodgkin lymphoma and other malignancies.
Contact Information
Website
www.ararisbiotech.com(Operating Subsidiary)
Corporate Office
- Riedhofstrasse 11
- Au
- 8804 Zurich
- Switzerland
Corporate Office
- Riedhofstrasse 11
- Au
- 8804 Zurich
- Switzerland
Araris Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 31-Mar-2025 | $1.14B | Completed | Generating Revenue | ||
| 9. Accelerator/Incubator | 05-May-2023 | Completed | Generating Revenue | |||
| 8. Early Stage VC | 11-Apr-2023 | Completed | Generating Revenue | |||
| 7. Early Stage VC (Series A) | 04-Oct-2022 | Completed | Generating Revenue | |||
| 6. Early Stage VC | 22-Oct-2020 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A) | 27-Jun-2019 | Cancelled | Startup | |||
| 4. Accelerator/Incubator | 27-Jun-2019 | Completed | Startup | |||
| 3. Accelerator/Incubator | Completed | Startup | ||||
| 2. University Spin-Out | 01-Jan-2019 | Completed | Startup | |||
| 1. Grant | 03-Oct-2018 | $20.6K | Completed | Startup |
Araris Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference |
Araris Comparisons
Industry
Financing
Details
Araris Competitors (59)
One of Araris’s 59 competitors is Akari Therapeutics, a Formerly VC-backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Akari Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| Cell Signaling Technology | Corporation | Danvers, MA | ||||
| Cytovance Biologics | Formerly PE-Backed | Oklahoma City, OK | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Byondis | Corporation | Nijmegen, Netherlands |
Araris Patents
Araris Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026215442-A1 | Antibody-drug conjugates comprising multiple payloads | Pending | 09-Apr-2025 | ||
| US-20260014265-A1 | Triple-payload antibody-drug conjugates (adcs) | Pending | 10-Jul-2024 | ||
| WO-2026013234-A1 | Triple-payload antibody-drug conjugates (adcs) | Pending | 10-Jul-2024 | ||
| AU-2024364674-A1 | Antibody-drug conjugates using two different types of topoisomerase i inhibitors | Pending | 15-Oct-2023 | ||
| EP-4731265-A1 | Antibody-drug conjugates using two different types of topoisomerase i inhibitors | Pending | 15-Oct-2023 | A61K47/68037 |
Araris Signals
Araris Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 4BIO Capital | Venture Capital | Minority | ||
| ETH Zurich | University | |||
| Innosuisse | Government | |||
| Institute for Follicular Lymphoma Innovation | Not-For-Profit Venture Capital | Minority | ||
| Kinled Holding | Family Office | Minority |
Araris Investments (2)
Araris’s most recent deal was a Corporate Asset Purchase with Innate Pharma (Portfolio of Transglutaminase Patents in Marseille, France). The deal was made on 24-Sep-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Innate Pharma (Portfolio of Transglutaminase Patents in Marseille, France) | 24-Sep-2024 | Corporate Asset Purchase | Buildings and Property | ||
| ARS Pharmaceuticals (Nectin-4 Antibody) | 17-Apr-2023 | Corporate Asset Purchase | Buildings and Property |
Araris FAQs
-
When was Araris founded?
Araris was founded in 2018.
-
Where is Araris headquartered?
Araris is headquartered in Zurich, Switzerland.
-
What is the size of Araris?
Araris has 23 total employees.
-
What industry is Araris in?
Araris’s primary industry is Drug Discovery.
-
Is Araris a private or public company?
Araris is a Private company.
-
What is the current valuation of Araris?
The current valuation of Araris is .
-
What is Araris’s current revenue?
The current revenue for Araris is .
-
How much funding has Araris raised over time?
Araris has raised $43.5M.
-
Who are Araris’s investors?
4BIO Capital, ETH Zurich, Innosuisse, Institute for Follicular Lymphoma Innovation, and Kinled Holding are 5 of 14 investors who have invested in Araris.
-
Who are Araris’s competitors?
Akari Therapeutics, Cell Signaling Technology, Cytovance Biologics, CytomX Therapeutics, and Byondis are some of the 59 competitors of Araris.
-
When was Araris acquired?
Araris was acquired on 31-Mar-2025.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process